Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 622.6 DKK 5.67% Market Closed
Market Cap: 2.8T DKK
Have any thoughts about
Novo Nordisk A/S?
Write Note

Intrinsic Value

The intrinsic value of one NOVO B stock under the Base Case scenario is 683.36 DKK. Compared to the current market price of 622.6 DKK, Novo Nordisk A/S is Undervalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NOVO B Intrinsic Value
683.36 DKK
Undervaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Novo Nordisk A/S

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Valuation History Unavailable

Historical valuation for NOVO B cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about NOVO B?
Bearish
Neutral
Bullish

Fundamental Analysis

622.6 DKK
+5.67%
+5.67%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Novo Nordisk A/S
DK
Pharmaceuticals
Market Cap
2.7T DKK
IPO
May 17, 1974
Employees
47 792
Denmark
Market Cap
2.7T DKK
Industry
Pharmaceuticals
IPO
May 17, 1974
Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Novo Nordisk A/S

Provide an overview of the primary business activities
of Novo Nordisk A/S.

What unique competitive advantages
does Novo Nordisk A/S hold over its rivals?

What risks and challenges
does Novo Nordisk A/S face in the near future?

Summarize the latest earnings call
of Novo Nordisk A/S.

What significant events have occurred
in Novo Nordisk A/S over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Novo Nordisk A/S.

Provide P/S
for Novo Nordisk A/S.

Provide P/E
for Novo Nordisk A/S.

Provide P/OCF
for Novo Nordisk A/S.

Provide P/FCFE
for Novo Nordisk A/S.

Provide P/B
for Novo Nordisk A/S.

Provide EV/S
for Novo Nordisk A/S.

Provide EV/GP
for Novo Nordisk A/S.

Provide EV/EBITDA
for Novo Nordisk A/S.

Provide EV/EBIT
for Novo Nordisk A/S.

Provide EV/OCF
for Novo Nordisk A/S.

Provide EV/FCFF
for Novo Nordisk A/S.

Provide EV/IC
for Novo Nordisk A/S.

Show me price targets
for Novo Nordisk A/S made by professional analysts.

What are the Revenue projections
for Novo Nordisk A/S?

How accurate were the past Revenue estimates
for Novo Nordisk A/S?

What are the Net Income projections
for Novo Nordisk A/S?

How accurate were the past Net Income estimates
for Novo Nordisk A/S?

What are the EPS projections
for Novo Nordisk A/S?

How accurate were the past EPS estimates
for Novo Nordisk A/S?

What are the EBIT projections
for Novo Nordisk A/S?

How accurate were the past EBIT estimates
for Novo Nordisk A/S?

Compare the revenue forecasts
for Novo Nordisk A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Novo Nordisk A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Novo Nordisk A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Novo Nordisk A/S compared to its peers.

Compare the P/E ratios
of Novo Nordisk A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Novo Nordisk A/S with its peers.

Analyze the financial leverage
of Novo Nordisk A/S compared to its main competitors.

Show all profitability ratios
for Novo Nordisk A/S.

Provide ROE
for Novo Nordisk A/S.

Provide ROA
for Novo Nordisk A/S.

Provide ROIC
for Novo Nordisk A/S.

Provide ROCE
for Novo Nordisk A/S.

Provide Gross Margin
for Novo Nordisk A/S.

Provide Operating Margin
for Novo Nordisk A/S.

Provide Net Margin
for Novo Nordisk A/S.

Provide FCF Margin
for Novo Nordisk A/S.

Show all solvency ratios
for Novo Nordisk A/S.

Provide D/E Ratio
for Novo Nordisk A/S.

Provide D/A Ratio
for Novo Nordisk A/S.

Provide Interest Coverage Ratio
for Novo Nordisk A/S.

Provide Altman Z-Score Ratio
for Novo Nordisk A/S.

Provide Quick Ratio
for Novo Nordisk A/S.

Provide Current Ratio
for Novo Nordisk A/S.

Provide Cash Ratio
for Novo Nordisk A/S.

What is the historical Revenue growth
over the last 5 years for Novo Nordisk A/S?

What is the historical Net Income growth
over the last 5 years for Novo Nordisk A/S?

What is the current Free Cash Flow
of Novo Nordisk A/S?

Discuss the annual earnings per share (EPS)
trend over the past five years for Novo Nordisk A/S.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Novo Nordisk A/S

Current Assets 195.2B
Cash & Short-Term Investments 74.9B
Receivables 79.6B
Other Current Assets 40.7B
Non-Current Assets 202.3B
Long-Term Investments 2B
PP&E 119.8B
Intangibles 54.5B
Other Non-Current Assets 25.9B
Current Liabilities 208.4B
Accounts Payable 24.1B
Other Current Liabilities 184.3B
Non-Current Liabilities 68.6B
Long-Term Debt 51.5B
Other Non-Current Liabilities 17.1B
Efficiency

Earnings Waterfall
Novo Nordisk A/S

Revenue
270.6B DKK
Cost of Revenue
-41.5B DKK
Gross Profit
229.1B DKK
Operating Expenses
-110.7B DKK
Operating Income
118.4B DKK
Other Expenses
-23.6B DKK
Net Income
94.7B DKK

Free Cash Flow Analysis
Novo Nordisk A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NOVO B Profitability Score
Profitability Due Diligence

Novo Nordisk A/S's profitability score is 86/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Exceptional 3-Year Average ROIC
Positive Gross Profit
86/100
Profitability
Score

Novo Nordisk A/S's profitability score is 86/100. The higher the profitability score, the more profitable the company is.

NOVO B Solvency Score
Solvency Due Diligence

Novo Nordisk A/S's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

78/100
Solvency
Score

Novo Nordisk A/S's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NOVO B Price Targets Summary
Novo Nordisk A/S

There are no price targets for NOVO B.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NOVO B?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for NOVO B is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

NOVO B News

Other Videos

See Also

Discover More
What is the Intrinsic Value of one NOVO B stock?

The intrinsic value of one NOVO B stock under the Base Case scenario is 683.36 DKK.

Is NOVO B stock undervalued or overvalued?

Compared to the current market price of 622.6 DKK, Novo Nordisk A/S is Undervalued by 9%.

Back to Top